MetaVia Inc. — Director's Dealing 2016

Aug 5, 2016

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Gemphire Therapeutics Inc. (GEMP)
CIK: 0001638287
Period of Report: 2016-08-04

Reporting Person: MATHIESEN JEFFREY S (Chief Financial Officer)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Employee Stock Option (right to buy)	$3.587	2025-09-24	Common Stock (51300)		Direct
8% Convertible Subordinated Promissory Note	$6.7059		Common Stock ()		Direct

Footnotes

F1: The options were granted on September 25, 2015. 3,207 options immediately vested on the grant date, and the remaining options vest in 36 equal monthly increments on the last day of each month, except for the last vesting period ending on August 31, 2018, where 1,333 options will vest.

F2: The note was issued in the original principal amount of $25,000. The outstanding principal and accrued interest on such note will automatically convert into shares of common stock, par value $0.001 per share, of Gemphire Therapeutics Inc. (the "Company") immediately prior to the closing of the Company's initial public offering. The note bears interest at a rate of 8% per annum. The note has accrued interest of $1,304 to date and will continue to accrue interest until conversion.